First Implant of RTI’s map3™ Cellular Allogeneic Bone Graft in a Foot and Ankle Procedure October 1, 2013

Surgical implant company RTI Surgical Inc. has seen a first implantation of the company’s map3™ Cellular Allogeneic Bone Graft implant in a foot and ankle procedure.

Background

Map3 cellular allogeneic bone graft is described as a natural and safe alternative to autograft. The product provides the three elements necessary for bone repair—osteogenesis, osteoinduction and osteoconduction — in a single allograft. Map3 incorporates multipotent adult progenitor cell-based (MAPC-based) technology with stem cells isolated from the same donor as the other bone material. The MAPC technology, licensed from Athersys, Inc. for this orthopedic application, represents a distinctive type of stem cell with recognized angiogenic and immuno-modulatory properties. Map3 will be available in multiple configurations and sizes, providing bone grafting options for various bone repair, reconstruction and fusion procedures.

Dr. Michael Lyons, DPM, an associate member of the American College of Foot and Ankle Surgeons, performed the implantation during a medial column fusion procedure in Indiana. He used the implant’s chips allograft configuration, one of two configurations that will be available.

Physician comments

“Taking into account the published MAPC™ research, I decided to use map3 in a complex case with an immune-compromised patient because it would support the patient’s ability to heal,” said Dr. Lyons. “I was impressed by the ease of use – it required very little time to prepare with simple instructions for preparation. I will definitely use map3 again when it’s appropriate for the patient’s case.”

Company comments 

“Dr. Lyons’ successful use of map3 in a foot and ankle procedure is an exciting new development following its use in spine procedures,” said Brian K. Hutchison, RTI president and CEO. “The MAPC-based technology offers the greatest potential to create high quality, innovative implants for our surgeons and their patients and will greatly enhance our company’s orthobiologics offerings. We anticipate a limited market release of the implant later this year.”

Source: RTI Surgical Inc., Business Wire

Posted in:
, .

Previous Article:

Next Article:

Comment:
Add your thoughts below...

  • Share This Article:


  • Comments

    Comments are closed.

    Leave a Reply